ArticleDrug design, development and therapy2018
Therapeutic effect of protease-activated receptor 2 agonist SLIGRL-NH
Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Dup15q model mice exhibit impaired gastrointestinal motility and a constipation-like phenotype, alleviated by prucalopride.Translational psychiatry · 2026Article
- Restore intestinal steady-state: new advances in the clinical management of chemotherapy-associated diarrhea and constipation.Journal of molecular histology · 2025Review
- Olive Oil Solution of Volatile Oil fromDrug design, development and therapy · 2025Article
- L. acidophilus/L. johnsonii ratio affects slow transit constipation in rats.Scientific reports · 2024Article
- Article
- Knockdown of miR-19a suppresses gastrointestinal dysmotility diarrhea after TBI by regulating VIP expression.Brain and behavior · 2023Article
- Engineered 5-HT producing gut probiotic improves gastrointestinal motility and behavior disorder.Frontiers in cellular and infection microbiology · 2022Article
- Preclinical experimental models for assessing laxative activities of substances/products under investigation: a scoping review of the literature.American journal of translational research · 2022Article
- Paeoniflorin Improved Constipation in the Loperamide-Induced Rat Model via TGR5/TRPA1 Signaling-Mediated 5-Hydroxytryptamine Secretion.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Comparative Study of Constipation Exacerbation by Potassium Binders Using a Loperamide-Induced Constipation Model.International journal of molecular sciences · 2020Article
- Expression of Proteinase-Activated Receptor 2 During Colon Volvulus in the Horse.Frontiers in veterinary science · 2020Article
- Buzhongyiqi Decoction Protects Against Loperamide-Induced Constipation by Regulating the Arachidonic Acid Pathway in Rats.Frontiers in pharmacology · 2020Article
- Effects ofBiomolecules · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the therapeutic effects of protease-activated receptor 2 (PAR-2) agonist SLIGRL-NH MATERIALS AND
methodsLoperamide was injected subcutaneously to induce constipation twice a day for 3 days. SD rats (n = 30) were randomly divided into five groups: non-constipation group (control, n = 6), constipation group (constipation, n = 6), constipation + SLIGRL-NH
resultsThe feeding and excretion behaviors, intestinal transit ratio, and the histological feature of the colon in the constipated rats were all improved by SLIGRL-NH
conclusionThese results suggested that SLIGRL-NH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.